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The finding that chromatin modifications are sensi-
tive to changes in cellular cofactor levels potentially
links altered tumor cell metabolism and gene expres-
sion. However, the specific enzymes andmetabolites
that connect these two processes remain obscure.
Characterizing these metabolic-epigenetic axes is
critical to understanding how metabolism supports
signaling in cancer, and developing therapeutic stra-
tegies to disrupt this process. Here, we describe
a chemical approach to define the metabolic regu-
lation of lysine acetyltransferase (KAT) enzymes.
Using a novel chemoproteomic probe, we identify
a previously unreported interaction between palmi-
toyl coenzyme A (palmitoyl-CoA) and KAT enzymes.
Further analysis reveals that palmitoyl-CoA is a
potent inhibitor of KAT activity and that fatty acyl-
CoA precursors reduce cellular histone acetylation
levels. These studies implicate fatty acyl-CoAs as
endogenous regulators of histone acetylation, and
suggest novel strategies for the investigation and
metabolic modulation of epigenetic signaling.
INTRODUCTION
Lysine acetylation plays a critical role in regulating chromatin
structure. By neutralizing the positive charge of histone tails,
acetylation serves to relax histone-DNA interactions and allows
trans-acting factors to access genomic chromatin (Roth et al.,
2001). Lysine acetylation also provides binding sites for effector
proteins known as bromodomains, which can directly stimulate
transcription by recruiting coactivators (Dhalluin et al., 1999).
Global reductions in histone acetylation are correlated with
aggressive disease and poor clinical outcome in many cancers
(Seligson et al., 2005, 2009), and small molecules that counteract
this profile and restore acetylation are validated therapeutic
agents (Marks and Breslow, 2007). Defining the cellular mecha-
nisms that regulate acetylation is thus of critical importance to
understanding the biology of cancer and developing novel stra-
tegies to combat disease.
Protein acetylation is established by the opposing functions of
lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) en-1030 Chemistry & Biology 22, 1030–1039, August 20, 2015 ª2015 Elzymes. In addition to their role in transcription, the activity of
these enzymes appears to be intimately linked to the metabolic
state of the cell (Meier, 2013). For example, KDAC activity can
be modulated by endogenous inhibitors such as diet-derived
short-chain fatty acids and ketone bodies (Donohoe et al.,
2012; Shimazu et al., 2013). By comparison, less is known about
the metabolic mechanisms that influence KAT activity. Disrupt-
ing production of the KAT cofactor acetyl coenzyme A (acetyl-
CoA) has been shown to inhibit histone acetylation (Comerford
et al., 2014; Wellen et al., 2009). However, since all characterized
human KATs exhibit Michaelis constants for acetyl-CoA far
below its estimated cellular concentration (Tanner et al.,
2000a; Thompson et al., 2001), it has been proposed that rather
than becoming inherently rate limiting, low acetyl-CoA levels
make KATs more susceptible to inhibition by CoA, an endoge-
nous feedback inhibitor (Albaugh et al., 2011; Lee et al., 2014).
Evidence from biochemical analyses and studies in yeast sug-
gest that the GCN5 family of KATs may be particularly suscepti-
ble to this mechanism of regulation, and thus may serve as crit-
ical integrators of metabolic and epigenetic signals (Cai et al.,
2011; Langer et al., 2002).
The proposed metabolic regulation of KAT activity by CoA led
us to consider whether other endogenous inhibitors of these
enzymes may exist. Cells contain a diverse repertoire of acyl-
CoAs (i.e. malonyl-, succinyl-, butyryl-, propionyl-, crotonyl-,
and palmitoyl-CoA). Due to their function as key intermediates
in different bioenergetic pathways, the concentration of these
molecules directly reflects the metabolic state of the cell.
Notably, while diverse lysine acylations have been character-
ized (Lin et al., 2012), no KAT enzyme has yet been discovered
that can utilize these ‘‘alternative’’ acyl-CoA cofactors at rates
comparable with that of acetyl-CoA. In contrast, extended
CoA analogs capable of making high-affinity bisubstrate inter-
actions with KATs are well known as inhibitors of acetylation
(Lau et al., 2000). Therefore, we hypothesized that metabolic
acyl-CoAs may serve as endogenous bisubstrate inhibitors of
KAT enzymes (Figure 1). Metabolic modulation of KAT activity
by acyl-CoAs may provide cells with a mechanism to integrate
changes in metabolic state and histone acetylation, and poten-
tially fine-tune gene expression under conditions of nutrient
stress.
To investigate this hypothesis, here we describe a chemical
proteomic approach to define acyl-CoA/KAT interactions in
complex proteomes. This approach enables the rapid, direct,
and quantitative study of acyl-CoA/KAT interactions in their
native contexts, is applicable to multiple KAT family members,sevier Ltd All rights reserved
KAT
acetyl-CoA
metabolic
acyl-CoA
Ac Me
Ac
Ac
acetylated histonehistone
Figure 1. Metabolic Regulation of Histone
Lysine Acetyltransferase Activity by Endog-
enous Acyl-CoAs
By antagonizing acetyl-CoA binding, metabolic
acyl-CoAs may inhibit lysine acetyltransferase
(KAT) activity, thereby transducing information
about the metabolic state of the cell to changes in
histone acetylation.and does not require reconstitution. Applying this approach, we
identified a previously unreported palmitoyl-CoA/KAT interac-
tion. Biochemical profiling reveals palmitoyl-CoA and other fatty
acyl-CoAs can inhibit KAT activity, with different KAT subfamilies
displaying distinct in vitro sensitivities to this inhibition. Adding a
palmitoyl-CoA precursor to cells or overexpressing fatty acyl-
CoA biosynthetic enzymes reduces cellular histone acetylation.
These studies suggest that fatty acyl-CoAs may constitute a
novel class of endogenous KAT inhibitors, and propose novel
strategies for the metabolic modulation of KAT activity.
RESULTS
A Sensitive Chemical Proteomic Method to Assess KAT
Active Site Occupancy
A major challenge to studying the metabolic regulation of KAT
activity is that their biologically relevant forms are multiprotein
complexes that are difficult to reconstitute in vitro (Roth et al.,
2001). Testing whether a metabolite interacts strongly with one
or more of these KAT complexes is thus a non-trivial task.
To address this challenge, we developed a chemoproteomic
approach to study the active site occupancy of intact, multipro-
tein KAT complexes. This strategy uses an enrichable active site
probe to detect catalytically competent KATs directly from cell
proteomes (Figure 2). To enable the study of the metabolically
sensitive KAT enzymes Gcn5 and pCAF, the probe ‘‘core’’ incor-
porates H3K14-CoA, a known high-affinity inhibitor of these two
enzymes (Lau et al., 2000). For our affinity purification element
we introduced a straightforward N-terminal biotin, designed
to enable copurification and identification of KAT complex
members, and increase the sensitivity of KAT detection by cir-
cumventing potentially low-yielding photocrosslinking steps
(Montgomery et al., 2014).
In pilot studies, HeLa cell proteomes incubated with H3K14-
CoA-biotin 1 (10 mM) were subjected to streptavidin-enrichment
and a mild wash step. Liquid chromatography-tandem mass
spectrometry (LC-MS/MS) analysis revealed enrichment of
Gcn5, as well as several members of its associated multiprotein
STAGA complex (Figure 2; Table S1). We also detected enrich-
ment of Mof, a member of the MYST KAT family, including
several proteins associated with its NSL complex. Interestingly,
copurification of members of other Mof-containing complexes
(MSL and MLL) was not observed. For both KAT complexes,
enrichment was competed by addition of an active site directed
ligand (Figure 2). This indicates that probe 1 is capable of profiling
the active site occupancy of KATswithin their endogenousmulti-Chemistry & Biology 22, 1030–protein complexes, and represents a major leap in sensitivity
over our previous efforts (Montgomery et al., 2014). In addition
to Gcn5, the humanGCN5 KAT family contains another member,
pCAF, which is 97.8% identical in the KAT catalytic domain but
is present at comparably lower levels in HeLa cell extracts.
Theoretically pCAF should be amenable to active site directed
enrichment by probe 1, but was not observed in our LC-MS/MS
datasets. To test whether immunoblotting could enable the active
sitemediated analysis of low-abundance KATs not observable by
LC-MS/MS, we subjected unfractionated HeLa cell lysates to a
single round of affinity enrichment by 1, followed by immunoblot-
ting with an anti-pCAF antibody. Indeed, we found pCAF was en-
riched by probe 1, in a manner that was sensitive to active site
competition. This likely reflects the signal amplification afforded
by chemiluminescent detection strategies, and highlights immu-
noaffinity profiling as an ideal approach for the targeted quantifi-
cation of KAT active site engagement.
Competitive Chemical Proteomic Profiling of Acyl-CoA/
KAT Interactions
We next assessed whether probe 1 could be applied in a
competitive chemoproteomic approach to study the metabolic
sensitivity of native, cellular KAT enzymes (Leung et al., 2003).
In this experiment, blockade of KAT active sites by a competing
acyl-CoA metabolite results in reduced enrichment of cellular
KATs (Gcn5, pCAF, or Mof), impeding their subsequent detec-
tion (Figure 3). Thus, in parallel, HeLa cell lysates were incubated
with a variety of CoA metabolites (CoA, acetyl-CoA, propionyl-
CoA, butyryl-CoA, malonyl-CoA, succinyl-CoA, crotonyl-CoA,
and palmitoyl-CoA; Figure S1A), followed by H3K14-CoA-biotin
1 enrichment and anti-KAT immunoblotting.
We observed an overall trend of metabolic acyl-CoAs inhibit-
ing pulldown of Mof > Gcn5 > pCAF (Figure 3). Since 1 likely
binds to these three KATs with differing affinities, it is logical
that each KAT may display different intrinsic sensitivities to
competition in this experiment. Therefore, we focused our anal-
ysis on the quantitative rank order trends ofmetabolite binding to
a single KAT, rather than absolute magnitude of competition be-
tween different KAT family members. The positive control acetyl-
CoA efficiently blocked enrichment of all three KATs, consistent
with its known strong interaction with these enzymes (Figure 3).
Competitive chemoproteomic analysis demonstrated that
the feedback inhibitor CoA also interacted strongly with all
three active sites, and was one of the strongest metabolic inhib-
itors tested. Interestingly, Gcn5 and pCAF interacted more
strongly with their feedback inhibitor (CoA) than their cofactor1039, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1031
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Figure 2. A Chemical Proteomic Strategy
for Profiling Cellular KAT Complexes
(A) Schematic of KAT chemical proteomic probe
(H3K14-CoA-biotin, 1) used in this study, with
ribbon representing H3 peptide. Full structure
of probe and competitor are provided in the
Supplemental Information.
(B) Spectral counts for KATs and complex mem-
bers enriched by 1.
(C) Immunoaffinity profiling of Gcn5, pCAF, and
Mof demonstrate active site dependent enrich-
ment of each KAT. Input represents the KAT
immunoblot signal from non-enriched control,
and competitor refers to the active site directed
ligand H3K14-CoA.(acetyl-CoA), a finding that was distinct from Mof (Figure 3). This
provides further evidence that GCN5 family members may be
particularly sensitive to changes in the acetyl-CoA/CoA ratio,
as has been previously proposed (Albaugh et al., 2011; Cai
et al., 2011; Lee et al., 2014; Wellen et al., 2009).
Next, we shifted our focus to investigating whether any meta-
bolic acyl-CoAs are capable of interacting strongly with KATs,
potentially indicating their ability to serve as alternative cofactors
or endogenous inhibitors of these enzymes. Propionyl- and bu-
tyryl-CoA are known to be able to function as alternative cofac-
tors for Gcn5 and pCAF (Leemhuis et al., 2008; Montgomery
et al., 2014), and strongly competed for their proteomic enrich-
ment. Mof also interacted strongly with these C3/C4 acyl-
CoAs, and propionyl-CoA antagonized Mof enrichment to a
similar degree as its natural substrate acetyl-CoA. The ability
of propionyl-CoA to function as a cofactor or inhibitor of Mof
has not been reported (Chen et al., 2007). Malonyl-, crotonyl-,
and succinyl-CoA did not interact strongly with Gcn5 or pCAF
(<50% inhibition of pulldown), while Mof was observed to
interact weakly with malonyl-CoA. However, we found that
palmitoyl-CoA competitively inhibited enrichment of all three
KAT enzymes (>50% inhibition of pulldown; Figure 3). Relative
to acetyl-CoA, palmitoyl-CoA most strongly antagonized Gcn5
pulldown, followed by Mof and pCAF. In addition to these KAT
catalytic domains, palmitoyl-CoA also antagonized enrichment
of the STAGA/PCAF component TRRAP (Figure S1B). This
indicates that palmitoyl-CoA is able to block the interaction of
H3K14-CoA-biotin 1 with a multiprotein KAT complex, presum-
ably by directly competing for the enzyme active site. Control
experiments showed that palmitoyl-CoA was not significantly1032 Chemistry & Biology 22, 1030–1039, August 20, 2015 ª2015 Elsevier Ltd All rights resehydrolyzed during these experiments
(Figure S2), suggesting that competition
was due to palmitoyl-CoA itself and not
a downstream effector or by-product.
Gcn5, pCAF, and Mof are all known to
inefficiently utilize extended acyl-CoA
analogs (Chen et al., 2007; Yang et al.,
2013), and our own studies provided no
evidence that these KATs were capable
of using palmitoyl-CoA as a substrate
(vide infra). These observations, coupled
with the potential significance of a link be-
tween transcriptional regulation and fattyacid metabolism, led us to further investigate palmitoyl-CoA as a
potentially novel, endogenous KAT inhibitor.
Biochemical Analysis of Fatty Acyl-CoA/KAT
Interactions
While the inhibition of KAT activity by palmitoyl-CoA has not been
previously reported, fatty acyl-CoAs and fatty acyl-CoA binding
proteins have been found in the nuclei of eukaryotic cells (Elholm
et al., 2000; Huang et al., 2004; Ves-Losada and Brenner, 1996).
Furthermore, these species have been proposed to regulate the
activity of transcription factors (Hertz et al., 1998), kinases, and
metabolic enzymes (Jenkins et al., 2011; Yang et al., 2005). To
extend these observations to KATs, we first used a known crystal
structure of the metabolically sensitive KAT Gcn5 to model the
human palmitoyl-CoA/Gcn5 complex (Figure 4A) (Poux et al.,
2002). The natural cofactor acetyl-CoA binds Gcn5 via hydrogen
bonds between the oxygen atoms of the pyrophosphate moiety
and the backbone amide nitrogens of Val587, Lys588, Gly589,
Thr592, and Lys624, aswell as between the phosphopantetheine
arm and backbone amides of Cys579 and Val581. Docking sug-
gests that palmitoyl-CoA has the capacity tomake identical inter-
actionswith theGcn5 cofactor binding site, potentially anchoring
the fatty acyl chain and allowing it tomake additional interactions
with hydrophobic surfaces in the substrate binding site, similar to
synthetic bisubstrate inhibitors (Figure 4A).
To biochemically characterize the effect of palmitoyl-CoA on
KAT activity, we applied a coupled-enzyme assay to monitor
histone peptide acetylation. To directly compare chemoproteo-
mic and in vitro biochemical methods, we analyzed metabolic
acyl-CoAs for inhibition of Gcn5 at a single concentrationrved
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Figure 3. Competitive Chemical Proteomic Profiling of Acyl-CoA/KAT Interactions
(A) Schematic depiction of strategy.
(B) Representative immunoblots depicting enrichment of Gcn5,Mof, and pCAF by probe 1 (10 mM) in the absence or presence of metabolic acyl-CoA competitors
(30 mM).
(C–E) Quantitative rank ordering of acyl-CoA interactions with Gcn5 (C), Mof (D), and pCAF (E), as analyzed via gel densitometry. Values represent the average ±
SD of three replicates, with percent competition calculated by comparing KAT pulldown in the presence and absence of each acyl-CoA.(20 mM). Consistent with our chemoproteomic analysis, signifi-
cant differences (p < 0.05) were seen between palmitoyl-CoA
and the weak interactors crotonyl-, malonyl-, and succinyl-
CoA (Figure S3). No turnover was observed in the absence of
acetyl-CoA, indicating that palmitoyl-CoA is not used by Gcn5
as a substrate. Further analysis revealed that palmitoyl-CoA
potently inhibits recombinant Gcn5 (Ki = 630 ± 80 nM) at levels
far below its critical micellar concentration (70 mM) (Constan-
tinides and Steim, 1985). Palmitoyl-CoA inhibition best fit a
model that was competitive with regard to acetyl-CoA (Fig-
ure 4B). Furthermore, free palmitic acid did not affect Gcn5 ac-
tivity (Figure S4), demonstrating that the C16 fatty acid must be
covalently anchored to CoA to mediate its inhibitory effect. To
evaluate specificity, we studied the effects of palmitoyl-CoA
on the prototypical KAT p300. Palmitoyl-CoA inhibits p300-
catalyzed acetylation, although less potently than Gcn5 (Ki =
8,750 ± 1,900 nM). Furthermore, we benchmarked the inhibitory
potency of palmitoyl-CoA against desulfo-CoA, a desulfurized
CoA analog that has previously been used to study feedback in-
hibition of Gcn5 and is compatible with KAT coupled-enzyme
assays (Tanner et al., 2000b). Desulfo-CoA inhibited Gcn5 less
potently than palmitoyl-CoA (Ki = 1,220 ± 190 nM), highlighting
palmitoyl-CoA as one of the most potent endogenous KAT-
inhibiting metabolites identified to date.
To confirm these results and better understand the structural
requirements for KAT inhibition, we next screened CoA, palmi-Chemistry & Biology 22, 1030–toyl-CoA, and related fatty acyl-CoAs for their effect on Gcn5
activity using an orthogonal, separation-based assay (Fanslau
et al., 2010). This assay monitors the ability of KATs to acetylate
a fluorescent peptide substrate, which can be separated from
non-acetylated peptides in a charged field and thus provide
a direct and quantitative readout of KAT activity. While not
amenable to the determination of biochemical inhibition con-
stants, this assay does enable the direct comparison of the inhib-
itory potency of CoA and palmitoyl-CoA (CoA itself is technically
incompatible with the coupled-enzyme method). Separation-
based analyses of KAT activity confirmed that palmitoyl-CoA
inhibited Gcn5 more potently than CoA (66% versus 29% inhibi-
tion at 10 mM, respectively). Expansion of this method to analyze
a fatty acyl-CoA panel found Gcn5 was inhibited more potently
by C18 fatty acyl-CoAs (linoleoyl- and oleoyl-CoA) than C14/
C16 (Figure 4C). Beyond these differences in magnitude of inhi-
bition, the larger general trend observed was that all fatty acyl-
CoAs, regardless of chain length or unsaturation, had the net
effect of inhibiting KAT activity (Figure 4C). The high number of
rotatable bonds in palmitoyl-CoA limits rigorous computational
treatment, and a definitive model of palmitoyl-CoA/Gcn5 binding
will require structural analyses. However, docking studies sup-
port the finding that Gcn5 can bind a variety of fatty acyl-
CoAs, as the majority of contacts of the fatty acyl chain are
made generically with hydrophobic surfaces in the shallow sub-
strate binding groove of the enzyme rather than in a deep,1039, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1033
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Figure 4. Biochemical Characterization of
Fatty Acyl-CoA/KAT Interactions
(A) Homology model of human Gcn5 bound
to bisubstrate inhibitor H3K14-CoA and palmi-
toyl-CoA.
(B) Analysis of metabolic inhibition of Gcn5 via
coupled-enzyme assay Lineweaver-Burk plot de-
picting acetyl-CoA competitive inhibition of Gcn5
by palmitoyl-CoA.
(C) Analysis of metabolic inhibition of Gcn5
via separation-based assay. Palmitoyl-CoA and
related fatty acyl-CoAs inhibit Gcn5 biochemical
activity more potently than CoA. Structures of fatty
acyl-CoAs are provided in Figure S1.specific binding pocket (Figure 4A). The ability of Gcn5 to pro-
miscuously interact with fatty acyl-CoAs is similar to the broad-
spectrum binding exhibited by fatty acid binding transcription
factors (Lin et al., 1999). These data also suggest that overall
cellular fatty acyl-CoA content, rather than any individual fatty
acyl-CoA signal, may be the most important determinant for
inhibition of cellular KAT activity by this mechanism.
Modulating Fatty Acyl-CoA Biosynthesis Can Affect
Histone Acetylation in Cells
Determining whether fatty acyl-CoAs can act as endogenous
inhibitors of KATs in cells is challenging due to many factors,
including the lack of cell permeability of these molecules, the
central role of fatty acyl-CoAs to many cell processes, and the
difficulty of quantifying subcellular fatty acyl-CoA concentra-
tions. Indeed, the overall nuclear/cytosolic concentration of fatty
acyl-CoAs, which our biochemical analyses indicate may be a
key regulator of KAT activity, has not been quantitatively deter-
mined for any cell line. Nevertheless, the inhibition constants
measured here are lower than the Km values that many long-
chain acyl-CoA metabolizing enzymes exhibit for palmitoyl-
CoA (1 mM) (Powell et al., 1985), and fatty acyl-CoA concen-
trations in the micromolar range have been demonstrated to1034 Chemistry & Biology 22, 1030–1039, August 20, 2015 ª2015 Elsevier Ltd All rights resemodulate the activity of many proteins
including glucokinase (Tippett and Neet,
1982), protein kinase C (Majumdar
et al., 1991), carnitine palmitoyltransfer-
ase (Agius et al., 1987), and the nuclear
thyroid hormone receptor (Li et al.,
1990). This suggests that the observed
inhibition of KATs by fatty acyl-CoAs
may be biologically relevant, and led us
to investigate the relationship between
fatty acyl-CoA biosynthesis and histone
acetylation in cells.
As already mentioned, fatty acyl-
CoAs are not directly cell permeable.
Therefore, we first evaluated the effect
of palmitate, a palmitoyl-CoA precursor,
on cellular histone acetylation. In
HEK293T cells, we found that supple-
mentation of media with palmitate
(0.1 mM) led to a slight, but measurable,
decrease in several histone marks,including H3K9Ac, H3K14Ac, H3K27Ac, and H4K8Ac (Figure 5).
However, this effect is small, and could be due to either stimula-
tion of fatty acyl-CoA/KAT interactions or KAT-independent, off-
target effects. Thus, to further implicate fatty acyl-CoAs directly
as inhibitors of histone acetylation, we tested how manipulation
of palmitoyl-CoA biosynthesis affected this process. Palmitate
is activated to palmitoyl-CoA by the activity of ATP-dependent,
long-chain acyl-CoA synthetase (ACSL) enzymes (Figure 5).
The human genome encodes five ACSL family members, and
related medium-chain acyl-CoA synthetases are known to
possess considerable overlap in their ability to activate palmitate
(Watkins et al., 2007). Therefore, we employed a gain-of-function
approach to test whether overexpression of a fatty acyl-CoA
biosynthetic enzyme further antagonized acetylation. As many
ACSL enzymes are membrane proteins, we chose an ACSL fam-
ily member (ACSL3) known to express partial nuclear membrane
localization as a potential candidate for the production of nuclear
fatty acyl-CoAs (Poppelreuther et al., 2012). ACSL3 was cloned
with a C-terminal FLAG tag into a mammalian expression vector
under control of a constitutive CMV promoter. Transient trans-
fection and overexpression of FLAG-ACSL3 in HEK293T cells
prominently reduced histone acetylation. H3K9 and H3K14
are known targets of GCN5 family KATs (Jin et al., 2011), andrved
A B
Figure 5. Cellular Effects of Palmitoyl-CoA Precursors and Palmitoyl-CoA Synthetases on Histone Acetylation
(A) Long-chain acyl-CoA synthetase (ACSL)-dependent formation of palmitoyl-CoA from palmitate.
(B) (Top) Effect of palmitate treatment and ACSL3 overexpression on histone acetylation in HEK293T cells. Values under each immunoblot represent the
densitometry quantified band intensity relative to the control (lane 1). All quantified values were normalized based on Ponceau staining to account for differences
in loading between different lanes (Figure S5A). (Bottom) Cytosolic/nuclear loading controls and verification of FLAG-ACLS3 overexpression.acetylation of each of these residues was strongly reduced.
H4K8 and H3K27, which are not Gcn5-regulated targets, were
also antagonized. However, acetylation of the cytoskeletal pro-
tein tubulin was not affected (Figure 5). Interestingly, overexpres-
sion of ACSL3 alone (without palmitate supplementation) was
also found to inhibit histone acetylation, suggesting that endog-
enous fatty acids may be mobilized to stimulate deacetylation in
an ACSL-dependent manner (Figure S5B).
We emphasize that these results must be interpreted with
caution, as ACSL3 overexpression may have effects on meta-
bolism and enzyme activity that facilitate KAT-independent
mechanisms of deacetylation and will require further analysis
to dissect. In particular, the KDAC enzyme SIRT6 has been
shown to be biochemically activated by long-chain fatty acids
(although this enzyme primarily acts on H3K9Ac/H3K56Ac sub-
strates, and thus would not explain the observed inhibition of H4
acetylation) (Feldman et al., 2013). However, the strong stimula-
tion of deacetylation by fatty acyl-CoA biosynthetic enzymes,
together with our biochemical analyses, are consistent with the
hypothesis that fatty acyl-CoAs may be capable of metabolically
facilitating cellular deacetylation programs by functioning as
endogenous inhibitors of KAT enzymes.
DISCUSSION
The discovery that chromatin-mediated signaling cascades are
sensitive to the metabolic state of the cell has the potential to
powerfully illuminate the etiology of cancer and also inspire
new therapeutic strategies. However, a major challenge lies in
identifying direct mechanistic links between metabolites andChemistry & Biology 22, 1030–specific chromatin modifiers. Here, we have applied a novel
competitive chemoproteomic approach to identify a metabolic-
epigenetic interaction that potentially links tumor hypoacetyla-
tion and altered lipid metabolism on a molecular level (Nomura
et al., 2010; Seligson et al., 2005). Palmitoyl-CoA is capable of
interacting with KATs in the context of their multiprotein com-
plexes and can potently inhibit their catalytic activity at concen-
trations <1 mM, making it one of the most potent metabolic
inhibitors of KAT activity characterized to date. Previous studies
have identified fatty acyl-CoA and fatty acyl-CoA binding
proteins in the nucleus (Elholm et al., 2000; Ves-Losada and
Brenner, 1996), and micromolar concentrations of palmitoyl-
CoA have been implicated in the regulation of many cellular pro-
teins, including transcription factors (Hertz et al., 1998).While the
literature and data are compelling, a relevant question is whether
fatty acyl-CoAs are able to accumulate in cells to concentrations
sufficient to affect KAT activity. One possibility is that fatty acyl-
CoAs may be supplied to KATs at high local concentrations by
fatty acyl-CoA binding proteins, as has been proposed for other
fatty acyl-CoA regulated enzymes (Elholm et al., 2000). Alterna-
tively, the finding that a wide range of fatty acyl-CoAs can inhibit
KATs suggests the potential for overall fatty acyl-CoA concen-
trations to reach levels sufficient to affect KAT activity.
While the subcellular concentrations (i.e. nuclear/cytosolic
versus mitochondrial) of fatty acyl-CoAs have never been quan-
titatively characterized, studies in rats have observed that
several abundant fatty acyl-CoAs are upregulated under condi-
tions of nutrient stress, such as fasting (Woldegiorgis et al.,
1985). Wellen and coworkers have previously drawn a direct cor-
relation between bioenergetic stress, reduced acetyl-CoA/CoA1039, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1035
ratio, and inhibition of histone acetylation (Lee et al., 2014;
Wellen et al., 2009). Our findings extend this paradigm, and sug-
gest that in some cases this phenomenon may be mediated by
additional metabolic factors such as palmitoyl-CoA. Interest-
ingly, a recent study observed that cells grown in galactose-
palmitate exhibit both increased fatty acid oxidation and greatly
reduced histone acetylation, relative to cells grown on traditional
high-glucose media (Pougovkina et al., 2014). Since fatty acid
oxidation requires transient synthesis of nuclear/cytosolic fatty
acyl-CoA, it is intriguing to speculate that direct inhibition of
KATs by endogenous fatty acyl-CoAs may play a role in this pro-
cess, possibly facilitating gene-expression programs that aid
adaptation to conditions of bioenergetic stress.
Finally, beyond the potential biological ramifications of these
findings, our results also suggest a solution to a long-standing
challenge in acetylation biology: how to deliver potent KAT-
inhibiting bisubstrate inhibitors to cells. Our studies imply that
metabolic acyl-CoAs are capable of inhibiting KAT-catalyzed
acetylation with some degree of selectivity. It is therefore
intriguing to speculate that this mechanism may be exploited
to manipulate the concentrations of metabolic acyl-CoAs,
thereby producing endogenous KAT bisubstrate inhibitors in
cells. Notably, a wide array of metabolites and xenobiotics are
known to be activated to CoA analogs via the activity of acyl-
CoA synthetase enzymes (Darnell and Weidolf, 2013). Defining
the tissue-specific production and interaction of thesemetabolic
acyl-CoAs with KATs may provide a new paradigm for the tar-
geted regulation of KAT activity. Such studies will require
improved tools for the rapid development of KAT-metabolite in-
teractions, as the human genome encodes at least 30 enzymes
that have demonstrated evidence of KAT activity, only three of
which were analyzed with the chemical proteomic approach re-
ported here. In the future, we envision that improved chemical
proteomic approaches will enable the generation of global KAT
cofactor affinity maps (Becher et al., 2013), providing novel in-
sights into the metabolic regulation of KAT activity and strategic
manipulation of acetylation-dependent signaling in disease.
SIGNIFICANCE
Recent studies have found that many chromatin-mediated
signaling cascades are regulated by the metabolic state of
the cell. One mechanism by which metabolism can affect
epigenetic signaling is through the production of endoge-
nous inhibitors of chromatin-modifying enzymes. Here, we
have developed a chemical proteomic strategy to enable
the identification of new endogenous inhibitors of KAT en-
zymes. These studies led to the identification of palmitoyl-
CoA, a metabolite whose KAT inhibitory properties have
been heretofore unstudied, as a potentially novel endoge-
nous inhibitor of KAT activity. Palmitoyl-CoA and related
fatty acyl-CoAs potently inhibit the prototypical KAT Gcn5,
and cell culture studies suggest (but do not conclusively
demonstrate) that this mechanism may be operable in cells.
These studies highlight the utility of chemical proteomic
methods to rapidly characterize metabolic-epigenetic inter-
actions, and propose that metabolic manipulation of endog-
enous inhibitors may be a viable strategy for modulating
KAT activity in vivo.1036 Chemistry & Biology 22, 1030–1039, August 20, 2015 ª2015 ElEXPERIMENTAL PROCEDURES
Compounds, Enzymes, and Materials
Recombinant p300 (1,195–1,662) and Gcn5 (497–662) were obtained from
Enzo. Acetyl-CoA, propionyl-CoA, butyryl-CoA, succinyl-CoA, crotonyl-CoA,
malonyl-CoA, and palmitoyl-CoA were synthesized according to published
procedures (Padmakumar et al., 1997). All synthesized CoA analogs were
purified by high-performance liquid chromatography, with purity verified by
LC-MS prior to use. Linoleoyl-CoA, myristoyl-CoA, oleoyl-CoA, and palmito-
leoyl-CoA were purchased from Sigma with purity verified by LC-MS prior to
use. H3K14-CoA and desulfo-CoA were synthesized according to previously
reported procedures (Chase et al., 1966; Montgomery et al., 2014; Zheng
et al., 2004). Qubit Protein Assay kit (Life Technologies) was used to determine
cell lysate and histone extract concentrations. Pyruvate dehydrogenase
(PDH), ketoglutarate dehydrogenase, and nicotinamide adenine dinucleotide
were purchased from Sigma. Lab-Chip EZ-Reader 12-sipper chip (#760404)
and ProfilerPro Separation Buffer (#760367) were purchased from Perkin-
Elmer. H3K9Ac (9649P), H3K14Ac (7627P), H3K27Ac (8173), H4K8Ac
(2594P), acetylated tubulin (5225P), glyceraldehyde-3-phosphate dehydroge-
nase (5174S), Gcn5 (3305S), and pCAF (3378S) antibodies were purchased
from Cell Signaling Technologies, while Mof (A300-992A-T) antibody was pur-
chased from Bethyl Laboratories.
Chemical Proteomic Analysis of KAT/Acyl-CoA Interactions
For each analysis, 50 ml of streptavidin-agarose resin (prewashed with 33 1ml
of PBS) was incubated with 10 mM H3K14-CoA-biotin (1) in 500 ml of PBS and
rotated for 1 hr at room temperature. Whole-cell lysates were clarified via filtra-
tion (EMD-Millipore, SLGV033RS), adjusted to a final protein concentration of
1.5 mg/ml, and split into 500 ml (0.75 mg) aliquots. For competitive samples,
the metabolic acyl-CoA or cognate competitor (H3K14-CoA) was preincu-
bated with lysate for 30 min on ice. Following equilibration, beads were pel-
leted by centrifugation (1400 rcf, 3 min) and the supernatant was removed,
before addition of the corresponding lysate sample. Samples were rotated
for 1 hr at room temperature, and pelleted by centrifugation (1400 rcf,
3 min). After removal of lysate solution, beads were washed with ice-cold
buffer (50 mM Tris-HCl [pH 7.5], 5% glycerol, 1.5 mM MgCl2, 150 mM NaCl,
3 3 500 ml) and collected in centrifugal filters (VWR, 82031-256). For western
blot analysis, samples were eluted in 13 SDS sample buffer (95C, 2 3
10 min). For proteomic analysis, 400 ml of trypsin buffer (50 mM Tris-HCl [pH
8.0], 1 M urea) was added to each sample, followed by 0.4 ml of 1 M CaCl2
and 4 ml of trypsin (0.25mg/ml), and digests were allowed to proceed overnight
at 37C. After extraction, tryptic peptide samples were acidified to a final con-
centration of 5% formic acid and frozen at 80C for LC-MS/MS analysis.
Continuous Assay for Lysine Peptide Acetylation: Coupled-Enzyme
Assay
KAT activity wasmeasured by a continuous coupled-enzyme assay (Kim et al.,
2000). In this assay, CoA produced by KAT-catalyzed acetylation is used by
PDH to produce the reduced form of NAD+ (NADH), which can be monitored
spectrophotometrically at 340 nm. Assays were performed in 150-ml volumes
containing 50 mM Bis-Tris, 50 mM Tris, 100 mM sodium acetate (TBA buffer,
pH 7.5), 5 mM MgCl2, 1 mM DTT, 2.4 mM pyruvate, 200 mM thiamine pyro-
phosphate, 200 mM NAD+, and 0.035 units of PDH (as defined by supplier),
unlabeled histone peptide (H3 5–20 for Gcn5, H4 3–14 for p300; 60 mM), and
150 nM Gcn5 or 100 nM p300. Reactions were plated in 96-well plates and
allowed to equilibrate at room temperature for 10min. Reactions were initiated
by addition of acetyl-CoA and analyzed continuously for 5 min by measuring
NADH production at 340 nm. Initial velocities were determined by linear
regression and background corrected by subtracting the rate of spontaneous
formation of CoA (determined from reactions lacking Gcn5/p300). Kinetic
parameters (Km and Vmax) for acetyl-CoA, and inhibition constants (Ki) for
palmitoyl- and desulfo-CoA were determined by holding the concentration
of substrate peptide constant (H3 5–20 for Gcn5, H4 3–14 for p300; 60 mM)
and initiating reactions with acetyl-CoA (4.1–33.3 mM) in the presence or
absence of inhibitor (0–20 mM). All calculations were performed using Graph-
pad Prism 6. Michaelis-Menten parameters for acetyl-CoA were calculated by
non-linear regression of initial velocities. Kinetic parameters for acetyl-CoA
were used to appropriately constrain non-linear regression analyses ofsevier Ltd All rights reserved
inhibitor data. Data were fit to equations for competitive, non-competitive, or
uncompetitive inhibition and assessed for global goodness of fit (R2 values)
to determine the optimal mode of inhibition. The inhibition constant Ki for
each inhibitor was computed by using equations Km(obs) = Km 3 (1 + [I]/Ki)
and Y = Vmax 3 X/(Km(obs) + X), where X is substrate concentration, Y is
response, [I] is the concentration of inhibitor, Vmax is the maximum response
in the absence of inhibitor (expressed in the same units as Y), and Km is the
Michaelis-Menten constant (expressed in the same units as X). Reported
values are based on competitive model of inhibition.
Separation-BasedAssay for LysinePeptide Acetylation:Microfluidic
Mobility Shift
Gcn5 activity was also measured using an orthogonal separation-based assay
(Fanslau et al., 2010). This method detects acetylation of a fluorescein isothio-
cyanate (FITC)-labeled Gcn5 substrate peptide (histone H3; FITC-Ahx-
QTARKSTGGKAPRKQL) based on its altered electrophoretic mobility relative
to non-acetylated peptide. Assays were performed in 30 ml of reaction buffer
(50 mM HEPES [pH 7.5], 50 mM NaCl, 2 mM EDTA, 2 mM DTT, 0.05% Triton
X-100) with KAT (GCN5 [100 nM], p300 [50 nM]) and FITC-peptide (FITC-H3 for
GCN5; FITC-H4 for p300). Reactions were plated in 384-well plates, allowed to
equilibrate at room temperature for 10 min, and initiated by addition of acetyl-
CoA (final concentration 0.63–10 mM). Reactions were monitored in real time
following transfer to a Lab-Chip EZ-Reader at ambient temperature and
analyzed by microfluidic electrophoresis. Optimized separation conditions
were: downstream voltage 500 V, upstream voltage 2,500 V, and a pres-
sure of 1.5 psi for FITC-H3 5–20 and FITC-H4 3–14. Percent conversion
was calculated by ratiometric measurement of substrate/product peak
heights. Percent activity represents the relative acetylation in inhibitor-treated
reactions relative to untreated control, measured in triplicate, and corrected for
non-enzymatic acetylation.
Docking Studies of Palmitoyl-CoA/Gcn5 Complex
The crystal structures of the KAT catalytic domain of humanGcn5 (PDB: 1Z4R)
andH3K14-CoA ligand (PDB: 1M1D) were retrieved from the PDB for use in the
docking calculations (Schuetz et al., 2007). The Protein Preparation Wizard
of the Schro¨dinger suite was used to prepare the binding site of Gcn5.
The protein was processed by assigning bond orders, adding hydrogens,
removing cocrystallized water molecules, and creating disulfide bonds.
Finally, a restrained minimization with a root-mean-square deviation of 0.30
was applied using the OPLS 2005 force field to optimize the hydrogen bond
network. Docking studies were performed using Glide (version 5.8; Schro¨-
dinger). The prepared Gcn5 structure was employed to generate the receptor
energy grid centered on the cocrystallized ligand. The extra-precision (XP)
docking protocol was used. Palmitoyl-CoA has 38 rotatable bonds, which
means the configuration space for docking poses is enormous. To facilitate
the sampling of the ligand conformations, we therefore set up a core constraint
for the flexible docking in Glide. This core constraint was defined using the
heavy atoms of the cofactor moiety of the cocrystallized ligand from PDB
structure 1Z4R. The docking poses obtained in this way were then redocked
again, but this time without constraints, using the refine mode in Glide.
Cellular Analyses of Histone Acetylation
HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine
serum and L-glutamine (2 mM). For histone acetylation analyses, HEK293T
cells were plated in six-well dishes (6 3 105 cells/well) and allowed to adhere
for 24 hr. At this point, transfections were performed using Lipofectamine 3000
(7.5 ml/well; Life Technologies) and plasmid DNA (2,500 ng) according to
the manufacturer’s protocol. After 6 hr the medium was removed, cells were
washed with PBS, and fresh medium was added containing either palmi-
tate-conjugated BSA (100 mM palmitate) or BSA control. Cells were incubated
with or without palmitate for 24 hr and harvested for histone extraction.
Following removal of media, cells were washed once with PBS and incubated
with 300 ml of Triton extraction buffer (TEB; PBS with 0.5% Triton X-100, 2 mM
PMSF, and 0.02% NaN3), harvested by gentle lifting, and transferred to micro-
centrifuge tubes. Samples were incubated in TEB for 30 min on ice, pelleted at
6,500 relative centrifugal force (rcf) for 10 min at 4C, and the supernatant
removed and saved for cytosolic protein analysis. Nuclei were resuspended,
washed again with TEB (150 ml), and pelleted at 6,500 rcf for 10 min at 4C.Chemistry & Biology 22, 1030–For acid extraction of histones, each pellet was treated with 0.4 N H2SO4
(75 ml) and rotated overnight at 4C. Samples were centrifuged at 11,000 rcf
for 10 min at 4C, and histones were precipitated from the supernatant by
addition of 20% TCA (750 ml). After at least 1 hr, samples were centrifuged
at 16,000 rcf for 10 min at 4C, and the pellets were washed with acetone/
0.1% HCl (750 ml) and neat acetone (750 ml), with centrifugations at 16,000
rcf for 10min at 4C following each wash. Samples were air-dried at room tem-
perature, dissolved in ddH2O, and quantified by Qubit Protein Assay kit (Life
Technologies). Samples were prepared for western blot analysis using Bis-
Tris NuPAGE gels (12%) and MES running buffer in Xcell SureLock MiniCells
(Invitrogen) according to the manufacturer’s instructions. Following antibody
incubation and washing, antibody binding was detected using LumiGLO
(Cell Signaling Technologies) and chemiluminescent signal visualized using
an ImageQuant Las4010 Digitial Imaging System (GEHealthcare). Immunoblot
signals were quantified using ImageQuant TL software (GE Healthcare).
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